shingrixhcp.com Open in urlscan Pro
34.107.225.66  Public Scan

Form analysis
1 forms found in the DOM

GET https://ShingrixHCP.com/search-result/

<form itemprop="potentialAction" itemscope="" itemtype="http://schema.org/SearchAction" class="cf-search-box initialized" action="https://ShingrixHCP.com/search-result/" method="get" data-search-suggestion-enabled="" data-search-suggestion-limit="5">
  <meta itemprop="target" content="https://ShingrixHCP.com/?_charset_=UTF-8&amp;q={search_term_string}">
  <input type="hidden" name="_charset_" value="UTF-8" data-di-id="di-id-925fa5f9-2523402d"><label for="search_0238637596" class="searchBox-label"> <span class="searchBox-title">Search</span> <input itemprop="query-input" type="text" name="q"
      id="search_0238637596" maxlength="2048" class="input-medium search-query" data-di-id="#search_0238637596"> </label><button type="submit" class="button" data-di-id="di-id-c95591a4-5e280d19"> . </button>
  <div class="tooltip">
    <div class="arrow"></div>
    <div class="tooltip-inner"> Tell us what you are looking for in the search box. </div>
  </div><input name=":cq_csrf_token" type="hidden" value="undefined" data-di-id="di-id-fd400cd0-4c7c2200">
</form>

Text Content

You are about to leave a GSK website. By clicking this link, you will be taken
to a website that is independent from GSK. The site you are linking to is not
controlled or endorsed by GSK, and GSK is not responsible for the content
provided on that site.


Yes No
Skip to main content

You are using an unsupported browser.

Some features of this site may not function properly. For optimal user
experience, please view this site in Chrome, Firefox, Safari, or Edge.



Timeout

As of January 2023: Some patients have had their co-pays change as a result of
the Inflation Reduction Act. Learn More.

For US HCPs

For US Healthcare Professionals

 * Patient Populations
   * 50 years and older
   * Immunocompromised, 18 years and older
 * Prescribing Info

 * Patient Populations
   * 50 years and older
   * Immunocompromised, 18 years and older
 * Prescribing Information
 * GSK MedInfo
 * Visit US Patient Site
 * Order SHINGRIX

Menu


Search .
Tell us what you are looking for in the search box.

Search


 * CDC Recommendations
 * Who To Vaccinate
   * Who To Vaccinate Overview
   * Shingles & Aging
   * Patient Profiles
 * Efficacy & Safety
   * Efficacy & Safety Overview
   * Efficacy Data
   * Safety Profile
   * Mechanism of Action
 * In Your Practice
   * In Your Practice Overview
   * Patient Counseling
   * Storage & Dosing
   * Reconstitution & Administration
   * Coverage & Coding
   * Support for Nurses
 * Resource Library
   * Resource Library Overview
   * On-Demand Videos
   * Resources
   * Educational Events

 * GSK MedInfo
 * Visit US Patient Site
 * Order SHINGRIX


IF YOU COULD
PREVENT SHINGLES,


WHY WOULDN'T YOU?


MAKE VACCINATION A PRIORITY YEAR-ROUND FOR YOUR PATIENTS 50 YEARS AND OLDER1,2

Not an actual patient.

Indication:


SHINGRIX is a vaccine indicated for prevention of herpes zoster (shingles) in
adults aged 50 years and older.

 

SHINGRIX is not indicated for prevention of primary varicella infection
(chickenpox).

We make it easy to order the vaccines you need online Order NOW

Educational Events

Plan ahead. Check the calendar to see the list of upcoming educational events
and sign up here.

 

 

On-Demand

Want to brush up on your SHINGRIX knowledge? We offer a range of educational
videos on topics that include highlights of the pivotal trials, MOA, and
reconstitution. Check out our On-Demand Videos.


ARE YOU PROTECTING YOUR PATIENTS 50 YEARS AND OLDER WITH SHINGRIX?1

The actions of you and your team can help prevent shingles in your patients.

Use our patient profiles to help identify the types of potential patients for
SHINGRIX.  

See Patient Profiles

Learn how to talk to your patients about what to expect, including common
adverse reactions.


Get Counseling Tips


CDC STATES THAT SHINGRIX IS RECOMMENDED FOR THE PREVENTION OF HERPES ZOSTER AND
RELATED COMPLICATIONS FOR IMMUNOCOMPETENT ADULTS AGED ≥50 YEARS.3

CDC Recommendations and Important Considerations

SHINGRIX is not indicated for prevention of herpes zoster-related complications.

 

CDC=Centers for Disease Control and Prevention.


YOU MAY ALSO BE INTERESTED IN:

Storage & Dosing


Learn how to store SHINGRIX and about the importance of proper dosing.

Coverage & Coding


Get product coding and coverage details for commercial medical benefit and
Medicare Part D insurance.

Safety Profile


See the safety results from 2
phase 3 clinical studies in adults 50 years and older.

Expand/Collapse
Indication & Important Safety Info
Indication

SHINGRIX is a vaccine indicated for prevention of herpes zoster (HZ) (shingles):

 * in adults aged 50 years and older.
 * in adults aged 18 years and older who are or will be at increased risk of HZ
   due to immunodeficiency or immunosuppression caused by known disease or
   therapy.

SHINGRIX is not indicated for prevention of primary varicella infection
(chickenpox).

Important Safety Information
 * SHINGRIX is contraindicated in anyone with a history of a severe allergic
   reaction (eg, anaphylaxis) to any component of the vaccine or after a
   previous dose of SHINGRIX
 * Review immunization history for possible vaccine sensitivity and previous
   vaccination-related adverse reactions. Appropriate medical treatment and
   supervision must be available to manage possible anaphylactic reactions
   following administration of SHINGRIX
 * In a postmarketing observational study, an increased risk of Guillain-Barré
   syndrome was observed during the 42 days following vaccination with SHINGRIX
 * Syncope (fainting) can be associated with the administration of injectable
   vaccines, including SHINGRIX. Procedures should be in place to avoid falling
   injury and to restore cerebral perfusion following syncope
 * Solicited local adverse reactions reported in individuals aged 50 years and
   older were pain (78%), redness (38%), and swelling (26%)
 * Solicited general adverse reactions reported in individuals aged 50 years and
   older were myalgia (45%), fatigue (45%), headache (38%), shivering (27%),
   fever (21%), and gastrointestinal symptoms (17%)
 * Solicited local adverse reactions reported in autologous hematopoietic stem
   cell transplant recipients (aged 18 to 49 and ≥50 years of age) were pain
   (88% and 83%), redness (30% and 35%), and swelling (21% and 18%)
 * Solicited general adverse reactions reported in autologous hematopoietic stem
   cell transplant recipients (aged 18 to 49 and ≥50 years of age) were fatigue
   (64% and 54%), myalgia (58% and 52%), headache (44% and 30%),
   gastrointestinal symptoms (21% and 28%), shivering (31% and 25%), and fever
   (28% and 18%)
 * The data are insufficient to establish if there is vaccine-associated risk
   with SHINGRIX in pregnant women
 * It is not known whether SHINGRIX is excreted in human milk. Data are not
   available to assess the effects of SHINGRIX on the breastfed infant or on
   milk production/excretion
 * Vaccination with SHINGRIX may not result in protection of all vaccine
   recipients

References: 1. Prescribing Information for SHINGRIX. 2. Berlinberg EJ, Kim E,
Deiner MS, Patterson C, Porco TC, Acharya NR. Sesonality of herpes zoster and
herpes zoster ophthalmicus. J Clin Virol. 2020;126:104306. 3. Dooling KL, Guo A,
Patel M, et al. Recommendations of the Advisory Committee on Immunization
Practices for use of herpes zoster vaccines. MMWR Morb Mortal Wkly Rep.
2018;67(3):103-108.

 * Educational Event Schedules
 * EHR Resources
 * CDC Supply Information
 * Vaccine Info Statement
 * Medical Inquiries

Questions About SHINGRIX?
Call: 1-800-772-9292

   Available Monday - Friday

    8:30 am to 5:30 pm ET

You are encouraged to report vaccine adverse events to the US Department of
Health and Human Services. Visit www.vaers.hhs.gov to file a report, or call
1-800-822-7967.

 * Legal Notice
 * Privacy Notice
 * Interest-based Ads
 * Contact Us
 * Unsubscribe

Your Privacy Choices

Trademarks are owned by or licensed to the GSK group of companies.




This website is funded and developed by GSK.
This site is intended for US healthcare professionals only.
©2022 GSK or licensor.
SGXWCNT230027 May 2023
Produced in USA.

Expand/Collapse
Indication & Important Safety Info
Indication

SHINGRIX is a vaccine indicated for prevention of herpes zoster (HZ) (shingles):

 * in adults aged 50 years and older.
 * in adults aged 18 years and older who are or will be at increased risk of HZ
   due to immunodeficiency or immunosuppression caused by known disease or
   therapy.

SHINGRIX is not indicated for prevention of primary varicella infection
(chickenpox).

SHINGRIX is a vaccine indicated for prevention of herpes zoster (HZ) (shingles):

 * in adults aged 50 years and older.
 * in adults aged 18 years and older who are or will be at increased risk of HZ
   due to immunodeficiency or immunosuppression caused by known disease or
   therapy.

SHINGRIX is not indicated for prevention of primary varicella infection
(chickenpox).

Important Safety Information
 * SHINGRIX is contraindicated in anyone with a history of a severe allergic
   reaction (eg, anaphylaxis) to any component of the vaccine or after a
   previous dose of SHINGRIX
 * Review immunization history for possible vaccine sensitivity and previous
   vaccination-related adverse reactions. Appropriate medical treatment and
   supervision must be available to manage possible anaphylactic reactions
   following administration of SHINGRIX

 * SHINGRIX is contraindicated in anyone with a history of a severe allergic
   reaction (eg, anaphylaxis) to any component of the vaccine or after a
   previous dose of SHINGRIX
 * Review immunization history for possible vaccine sensitivity and previous
   vaccination-related adverse reactions. Appropriate medical treatment and
   supervision must be available to manage possible anaphylactic reactions
   following administration of SHINGRIX

Chat with GSKBack to Top



This site uses cookies and similar technologies (collectively, "cookies") to
enhance your website experience and track the site's performance. These cookies
are automatically enabled. By using this site, you agree to our use of these
cookies in accordance with our Privacy Notice. Click on Privacy Choices below to
manage your preferences, including to opt out of the sale or sharing of your
information.

Privacy Choices

Managing Privacy Options

OPT OUT OF SALE AND SHARING OF INFORMATION

Your state law may allow you the right to opt out of the sale or sharing of your
personal information for targeted advertising. You may opt out of such sale or
share via the toggle available to you for "Targeting Cookies," and selecting the
"Confirm my choices” button below. To limit sale or sharing of your information
for targeting advertising offline, please see the "Cookies and Targeted
Advertising Choices," section in the Privacy Notice and submit the required
form.

Strictly Necessary Cookies Always Active

Necessary for the website to function appropriately, such as to store session
data during a website visit, to manage cookie and tag preferences, and to
protect the security of the website. In addition, some of these cookies are set
in response to actions made by you which amount to a request for services, such
as setting your privacy preferences, logging in, or filling in forms.

Performance Cookies Always Active

Enable the website to provide enhanced functionality and personalization, such
as by helping us to measure how many visitors come to our websites, what sites
our website visitors come from, and how often certain pages on our website are
viewed. These cookies may be set by us or by third party providers, like our
analytics service providers, whose services we have added to our pages.

Targeting Cookies

Allow us to target and re-target you with relevant advertising. We and our
advertising partners use information collected through these technologies to
infer your interests in order to serve you more relevant advertisements on other
sites. If you don’t allow these cookies, you will receive advertising, but it
may be less relevant to you.

Confirm my choices